Cargando…

Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients

BACKGROUND: Enzyme replacement therapy is currently the only approved therapy for Fabry disease. From June 2009 on, viral contamination of Genzyme's production facility resulted in a worldwide shortage of agalsidase beta leading to involuntary dose reductions (approved dose 1 mg/kg/eow, reduced...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smid, Bouwien E, Rombach, Saskia M, Aerts, Johannes MFG, Kuiper, Symen, Mirzaian, Mina, Overkleeft, Hermen S, Poorthuis, Ben JHM, Hollak, Carla EM, Groener, Johanna EM, Linthorst, Gabor E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219561/ https://www.ncbi.nlm.nih.gov/pubmed/22041095 http://dx.doi.org/10.1186/1750-1172-6-69

Ejemplares similares

Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg
por: Vedder, Anouk C., et al.
Publicado: (2007)

Cost-effectiveness of enzyme replacement therapy for Fabry disease
por: Rombach, Saskia M, et al.
Publicado: (2013)

Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome
por: Rombach, Saskia M., et al.
Publicado: (2012)

Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain
por: Rombach, Saskia M, et al.
Publicado: (2013)

Letter concerning “Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha”, by Tanaka et al.
por: Linthorst, Gabor E., et al.
Publicado: (2010)

Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study
por: Arends, Maarten, et al.
Publicado: (2018)

Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients
por: Smid, Bouwien E., et al.
Publicado: (2016)

Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?
por: Pisani, Antonio, et al.
Publicado: (2015)

Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation
por: van Kuilenburg, André B. P., et al.
Publicado: (2023)

Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders
por: Hollak, Carla EM, et al.
Publicado: (2011)

Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
por: Germain, Dominique P, et al.
Publicado: (2015)

Clinical course of patients with Fabry disease who were switched from agalsidase-β to agalsidase-α
por: Tsuboi, Kazuya, et al.
Publicado: (2014)

Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease
por: Shu, Liming, et al.
Publicado: (2014)

Agalsidase alfa (Replagal(™)) in the treatment of Anderson-Fabry disease
por: Pastores, Gregory M
Publicado: (2007)

Update on role of agalsidase alfa in management of Fabry disease
por: Ramaswami, Uma
Publicado: (2011)

Prevalence of symptoms in female Fabry disease patients: a case-control survey
por: Bouwman, Machtelt G., et al.
Publicado: (2012)

Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)
por: Tsuboi, Kazuya, et al.
Publicado: (2012)

Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation
por: Warnock, David G., et al.
Publicado: (2012)

CORRIGENDUM: Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)
Publicado: (2012)

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
por: Beck, Michael, et al.
Publicado: (2015)

Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry
por: Ortiz, Alberto, et al.
Publicado: (2016)

Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions
por: Kok, Ken, et al.
Publicado: (2021)

Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease
por: Cybulla, Markus, et al.
Publicado: (2022)

Poikilothermia in a 38-year-old Fabry patient
por: Biegstraaten, Marieke, et al.
Publicado: (2010)

Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy
por: Warnock, David G, et al.
Publicado: (2015)

Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment
por: Kampmann, Christoph, et al.
Publicado: (2015)

Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients
por: Tsuboi, Kazuya, et al.
Publicado: (2017)

Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies
por: Aerts, Johannes M. F. G., et al.
Publicado: (2011)

Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease
por: Goláň, Lubor, et al.
Publicado: (2015)

Erratum to: Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment
por: Kampmann, Christoph, et al.
Publicado: (2016)

Reduction of agalsidase beta infusion time in patients with fabry disease: A case series report and suggested protocol
por: Sánchez-Purificación, Aquilino, et al.
Publicado: (2021)

Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol
por: Riccio, Eleonora, et al.
Publicado: (2021)

Safety of a protocol for reduction of agalsidase beta infusion time in Fabry disease: An Italian multi-centre study
por: Mignani, Renzo, et al.
Publicado: (2021)

Membranous nephropathy without vacuolated podocytes in Fabry disease treated with agalsidase-β and carbamazepine: A case report
por: Kanai, Takahiro, et al.
Publicado: (2022)

Pain management strategies for neuropathic pain in Fabry disease - a systematic review
por: Schuller, Y., et al.
Publicado: (2016)

Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotype
por: Hopkin, Robert J., et al.
Publicado: (2020)

Erratum to: Pain management strategies for neuropathic pain in Fabry disease - a systematic review
por: Schuller, Y., et al.
Publicado: (2016)

Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study
por: Schiffmann, Raphael, et al.
Publicado: (2014)

Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis
por: Hughes, Derralynn, et al.
Publicado: (2021)

The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process
por: Khan, Aneal, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mq1f6r2f5mei9i429qm0nnd1l3